Hedenus et al. were the first to investigate whether IV iron would increase Hb in patients with lymphoid malignancies and functional iron deficiency (Hb 85–105 g/L and SF > 30 μg/L for women or >40 μg/L for men, TSAT ≤ 20%). This evidence concerns the gene GSTM1 and Iron deficiency anemia.